Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts

In an attempt to establish a specific drug regimen that would retard neointimal fibrous thickening (NFT) and promote patency of small arterial grafts, we studied acute platelet accumulation and 3-month patency of 4 mm polytetrafluoroethylene (PTFE) grafts in dogs treated with oral aspirin (2 mg/kg/day) in combination with dipyridamole (5 mg/kg/day) (ASA/D) or ticlopidine (25 mg/kg/day) (T). After 3 days of treatment, 15 dogs were given indium 111-labeled autologous platelets and then had bilateral femoral artery grafts placed (control, 10 grafts; each drug group, 10 grafts). The calculated graft radioactivity expressed as average counts per 10 minutes +/- standard error of the mean (SEM) was as follows: control = 542,003 +/- 63,991; ASA/D = 135,163 +/- 14,443 (p less than 0.001, Student's t test); T = 104,650 +/- 14,004 (p less than 0.001). Bilateral femoral artery and carotid artery grafts were placed in 15 other dogs (control, 20 grafts; each drug group, 20 grafts). Three months later the 60 grafts were excised and their patency recorded: control = 20% (4 of 20 grafts); ASA/D = 70% (12 of 17 grafts) (p less than 0.01, chi-square analysis); T = 30% (6 of 20 grafts) (p greater than 0.05). Mean anastomotic NFT +/- SEM of each graft was measured with an ocular micrometer: control = 1.6 +/- 0.2 mm; ASA/D = 0.7 +/- 0.2 mm (p less than 0.001, Student's t test); T = 1.3 +/- 0.2 mm (p greater than 0.1).(ABSTRACT TRUNCATED AT 250 WORDS)